Naoki Haratake
Overview
Explore the profile of Naoki Haratake including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
995
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, et al.
J Thorac Oncol
. 2024 Dec;
20(3):399.
PMID: 39692639
No abstract available.
2.
3.
Nomura K, Takada K, Kinoshita F, Muto S, Matsubara T, Kouki Y, et al.
Int J Cancer
. 2024 Nov;
156(7):1480-1491.
PMID: 39569608
The expression of programmed cell death-ligand 1 (PD-L1) and mutation in epidermal growth factor receptor (EGFR) are biomarkers used for perioperative treatment of lung adenocarcinoma. However, the clinical significance of...
4.
Ozawa H, Haratake N, Nakashoji A, Daimon T, Bhattacharya A, Wang K, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062082
Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There...
5.
Bhattacharya A, Wang K, Penailillo J, Chan C, Fushimi A, Yamashita N, et al.
Oncogene
. 2024 May;
43(28):2199-2214.
PMID: 38802648
The MUC1 gene evolved in mammals for adaptation of barrier tissues in response to infections and damage. Paraspeckles are nuclear bodies formed on the NEAT1 lncRNA in response to loss...
6.
Wang K, Bhattacharya A, Haratake N, Daimon T, Nakashoji A, Ozawa H, et al.
Cell Death Dis
. 2024 May;
15(5):330.
PMID: 38740827
The long non-coding RNA X-inactive specific transcript (lncRNA XIST) and MUC1 gene are dysregulated in chronic inflammation and cancer; however, there is no known interaction of their functions. The present...
7.
Nakashoji A, Haratake N, Bhattacharya A, Mao W, Xu K, Wang K, et al.
Cancer Res Commun
. 2024 Apr;
4(5):1268-1281.
PMID: 38619287
Significance: This work reports a previously unrecognized role for MUC1-C in driving STAT1-mediated chronic inflammation with the progression of HNSCC and identifies MUC1-C as a druggable target for advanced HNSCC...
8.
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, et al.
Eur J Cancer
. 2024 Feb;
201:113951.
PMID: 38417299
Objectives: To clarify the impact of central nervous system (CNS) metastasis on performance status (PS) at relapse, on subsequent treatment(s), and on survival of patients with lung adenocarcinoma harboring common...
9.
Daimon T, Bhattacharya A, Wang K, Haratake N, Nakashoji A, Ozawa H, et al.
Cell Death Discov
. 2024 Jan;
10(1):9.
PMID: 38182558
The oncogenic MUC1-C transmembrane protein is a critical effector of the cancer stem cell (CSC) state. Addiction to MUC1-C for self-renewal in the progression of human cancers has emphasized the...
10.
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, et al.
J Thorac Oncol
. 2023 Nov;
19(3):434-450.
PMID: 37924972
Introduction: Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with...